Western Reader
In a bold and visionary move, Pfizer, the pharmaceutical titan, is set to revolutionize the field of cardiovascular health.
The company’s strategic acquisition of Arena Pharmaceuticals, a leader in immuno-inflammatory disease treatments, positions Pfizer at the forefront of a new era in patient care.
This merger, valued at $6.7 billion, highlights Pfizer’s commitment to addressing the global rise in heart-related issues.
Pfizer’s innovative approach to healthcare is exemplified by its groundbreaking medications, Etrasimod and Temanogrel.
Etrasimod, a revolutionary treatment for inflammatory conditions, is one of the key assets obtained through the acquisition of Arena Pharmaceuticals. On the other hand, Temanogrel, a drug crucial in treating microvascular obstruction, is expected to play a significant role as cases of myocarditis increase worldwide.
Pfizer Unveils New Cardiovascular Drugs To Treat ‘Sudden’ Spike in Heart Problems
Myocarditis is a side effect of Pfizer’s Covid jabs.
The ruling elites have perfected the Hegelian Dialectic (problem-reaction-solution) into a fine art.
https://t.co/eJ9JBJRGeR via @realtpv— Countess Myo-Carditis ❌VerseCannon❌💄 (@VerseCannon) August 4, 2023
The pharmaceutical giant’s expansion into the field of heart inflammation demonstrates its dominance in the cardiovascular drugs market. This strategic move is expected to generate significant profits and solidify Pfizer’s position as a leader in the industry.
Central to Pfizer’s mission is addressing the spike protein syndrome, a chronic inflammation triggered by Pfizer’s Covid vaccinations. This unwavering commitment to health aligns seamlessly with Pfizer’s ethos and solidifies its position as a visionary healthcare leader.
The National Institutes of Health (NIH) recently revealed a comprehensive range of cardiovascular complications associated with Covid-19 mRNA vaccines.
These complications include pericarditis, myocarditis, hypertension, hypotension, arrhythmia, cardiogenic shock, stroke, myocardial infarction, intracranial hemorrhage, thrombosis, and pulmonary embolism.
Of particular concern is arterial thrombosis, which can lead to various health problems similar to those reported among athletes, military personnel, and public figures who have received Covid vaccinations.
Pfizer’s acquisition of Arena Pharmaceuticals holds promising prospects for its stakeholders. Investors are expected to benefit from the increasing cases of vascular clotting observed in recent years.
These cases have shown a direct correlation with immuno-inflammatory diseases, which Pfizer’s acquisition of Arena Pharma is uniquely positioned to address.
Were you injected with a COVID-19 vaccine? If so, were you informed that the new drugs were still in phase 3 clinical trials?
Pfizer’s clinical trial ends in Feb 2024 for adults and in July 2024 for children.
If you were not informed, please report the crime.https://t.co/sgtqBDjA2h— Logical Scot (@LogicalScot) August 2, 2023
Arterial thrombosis, characterized by the formation of blood clots in arteries, poses a significant threat.
Its consequences, including acute coronary syndrome and stroke, resemble the distressing cases reported among individuals who have received Covid vaccinations, such as athletes, military personnel, and public figures.
With an estimated surge of approximately 10 million patients facing cardiovascular obstructions by 2025, Pfizer’s APD418 offers hope.
Chris Cabell MD, Senior Vice President of Arena, envisions an unprecedented impact: “With limited treatment options for the projected 10 million DHF patient hospital visits, APD418 is poised to redefine patient care.”
This article appeared in The State Today and has been published here with permission.
GIPHY App Key not set. Please check settings